Patent litigators from Fish & Richardson, an intellectual house regulation company, regaled audiences throughout a webinar, entitled “Biosimilars: 2022 Yr-in-Evaluation,” covering all the major biosimilar regulatory and authorized selections through 2022, including updates on patent disputes and anti-believe in investigations. Approvals and Launches Jenny Shmuel, JD, principal at Fish & Richardson, delivered an ignore of the Food and drug administration approvals and US launches in the biosimilars area. For the duration of 2022, there had been 7 approvals, 4 launches, and 2 interchangeability designations (Desk 1). Additionally, there were 11 biologics license application (BLA) submissions for biosimilars. Because the very first quarter (Q1) of 2020, uptake of biosimilars has grown…